title: Patients with bisphosphonate-associated osteonecrosis of the jaw have unmodified levels of soluble vascular endothelial growth factor receptor 1.
authors.forename: Andrea
authors.initials: A
authors.lastname: Alonci
authors.forename: Alessandro
authors.initials: A
authors.lastname: Allegra
authors.forename: Giacomo
authors.initials: G
authors.lastname: Bellomo
authors.forename: Eugenia
authors.initials: E
authors.lastname: Quartarone
authors.forename: Giacomo
authors.initials: G
authors.lastname: Oteri
authors.forename: Enrico
authors.initials: E
authors.lastname: Nastro
authors.forename: Domenico
authors.initials: D
authors.lastname: Cicciù
authors.forename: Francesco Saverio
authors.initials: FS
authors.lastname: De Ponte
authors.forename: Caterina
authors.initials: C
authors.lastname: Musolino
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004164:Diphosphonates / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy*; D010020:Osteonecrosis / Q000139:chemically induced*; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000097:blood*